The market for therapeutic apoptosis modulators is currently only emerging.
However, over the five-year time course of this analysis, significant progress
is anticipated with respect to the realization of the incredible potential
offered by certain apoptosis modulators.
Theta' s report focuses on a complete description of advances made in
developing and bringing therapeutic apoptosis modulators to markets worldwide
and includes an analysis of probable future developments in the treatment of
variety of diseases and conditions such as, cancer, cardiovascular disease,
autoimmune diseases, infectious diseases, Alzheimer' s disease, Parkinson' s
disease, HIV/AIDS, and organ transplant rejection.
Major therapeutic targets of apoptosis-based compounds discussed in the
report include:
- Caspase activators and inhibitors
- Bcl-2 modulators
- p53 modulators
- Inhibitors of apoptosis proteins (IAPs)
- Protein kinase pathway modulators
- Mixed lineage kinase inhibitor
- Multiple signal transduction regulators
View Cart
